The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.
 
Antonio Giordano
Consulting or Advisory Role - Pfizer; Pfizer
 
Michail Ignatiadis
Honoraria - Novartis and Seattle Genetics
Research Funding - Pfizer, Roche, Inivata Inc, Natera Inc, and Gilead (Inst)
Travel, Accommodations, Expenses - Roche, AstraZeneca, and Gilead
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - Adium Pharma; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); ICON Clinical Research (Inst); INC Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Servier (Inst); Syneos Health (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi-Sankyo; Exact Sciences; GE Healthcare; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche; SAGA Diagnostics
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Menarini Group; Novartis; Pfizer
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); SAGA Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
Binghe Xu
Consulting or Advisory Role - Napo Pharmaceuticals, Puma Biotechnology, Mylan, Eisai, Daiichi Sankyo; Research Funding: OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Astellas Pharma, Pionyr, Taiho Oncology, Veru, Gl
Travel, Accommodations, Expenses - Merck, AstraZeneca, Gilead Sciences
 
Alicia M Vana
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jason Gong
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Ariadna Holynskyj
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Prashanth Gopalakrishna
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)